Continuing this post, here's an excerpt from the abstract from a Journal of Alzheimer's Disease recent article:
"We summarize the in vivo and in vitro research describing the
mechanisms of action in which curcumin modifies AD pathology: curcumin
inhibits the formation and promotes the disaggregation of amyloid-β
plaques, attenuates the hyperphosphorylation of tau and enhances its
clearance, binds copper, lowers cholesterol, modifies microglial
activity, inhibits acetylcholinesterase, mediates the insulin signaling
pathway, and is an antioxidant. In conclusion, curcumin has the
potential to be more efficacious than current treatments. However, its
usefulness as a therapeutic agent may be hindered by its low
bioavailability. If the challenge of low bioavailability is overcome,
curcumin-based medications for AD may be in the horizon."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.